Thrombocytopenia: Optimizing approaches in cancer patients

Caroline Piatek, Mojtaba Akhtari

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of  hrombocytopenia in the cancer setting In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles In this issue of ONCOLOGY Dr Kuter insightfully summarizes the differential diagnosis and management of thrombocytopenia in cancer patients[1] Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of hrombocytopenia in the cancer setting[2] In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles

Original languageEnglish (US)
JournalONCOLOGY (United States)
Volume29
Issue number4
StatePublished - Jan 1 2015

Fingerprint

Thrombocytopenia
Drug Therapy
Neoplasms
Differential Diagnosis
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Thrombocytopenia : Optimizing approaches in cancer patients. / Piatek, Caroline; Akhtari, Mojtaba.

In: ONCOLOGY (United States), Vol. 29, No. 4, 01.01.2015.

Research output: Contribution to journalArticle

Piatek, Caroline ; Akhtari, Mojtaba. / Thrombocytopenia : Optimizing approaches in cancer patients. In: ONCOLOGY (United States). 2015 ; Vol. 29, No. 4.
@article{cf1b651275844b8291b9d0905c606ff0,
title = "Thrombocytopenia: Optimizing approaches in cancer patients",
abstract = "Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of  hrombocytopenia in the cancer setting In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15{\%} of treatment cycles and chemotherapy delays in 6{\%} of cycles In this issue of ONCOLOGY Dr Kuter insightfully summarizes the differential diagnosis and management of thrombocytopenia in cancer patients[1] Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of hrombocytopenia in the cancer setting[2] In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15{\%} of treatment cycles and chemotherapy delays in 6{\%} of cycles",
author = "Caroline Piatek and Mojtaba Akhtari",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "29",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Thrombocytopenia

T2 - Optimizing approaches in cancer patients

AU - Piatek, Caroline

AU - Akhtari, Mojtaba

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of  hrombocytopenia in the cancer setting In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles In this issue of ONCOLOGY Dr Kuter insightfully summarizes the differential diagnosis and management of thrombocytopenia in cancer patients[1] Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of hrombocytopenia in the cancer setting[2] In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles

AB - Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of  hrombocytopenia in the cancer setting In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles In this issue of ONCOLOGY Dr Kuter insightfully summarizes the differential diagnosis and management of thrombocytopenia in cancer patients[1] Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of hrombocytopenia in the cancer setting[2] In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles

UR - http://www.scopus.com/inward/record.url?scp=84927732324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927732324&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84927732324

VL - 29

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 4

ER -